BusinessCyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic PathwaysBy Nasdaq OMXApr 2, 2017, 5:00 PM UTC
BusinessClinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s DiseaseBy Nasdaq OMXApr 2, 2017, 12:00 PM UTC
BusinessForward Pharma Intends to Appeal Decision in Patent Interference Proceeding with Biogen Inc.By Nasdaq OMXMar 31, 2017, 10:59 PM UTC
BusinessEight Posters Based on MacroGenics-developed Molecules Featured at AACR Annual Meeting 2017By Nasdaq OMXMar 31, 2017, 11:30 AM UTC
BusinessAkari Therapeutics Announces FDA Fast Track Designation For CoversinBy Nasdaq OMXMar 30, 2017, 8:02 PM UTC
BusinessMacroGenics to Present at the Needham Healthcare ConferenceBy Nasdaq OMXMar 29, 2017, 9:30 PM UTC
BusinessGlobal Blood Therapeutics to Present at the 16th Annual Needham Healthcare ConferenceBy Nasdaq OMXMar 29, 2017, 8:13 PM UTC
BusinessGlobal Blood Therapeutics to Present at the 16th Annual Needham Healthcare ConferenceBy Nasdaq OMXMar 29, 2017, 8:13 PM UTC
